• Explore /
  • Poster
  • / Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.

Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.

Abstract Poster

Authors

null

Chun Yew Fong

Austin Health/Olivia Newton-John Cancer Research & Wellness Centre, Heidelberg, Australia

Chun Yew Fong , Andrew H. Wei , Mark G. Frattini , Meagan Jacoby , Uma Borate , Katharina S. Gotze , Jacqueline Suen Garcia , Daniel Aaron Pollyea , Leanne Holes , Ying Zhou , Kaffa Mussumeh Fakouhi , Joel Leverson , Jason G Harb , Suresh K. Agarwal , Faraneh Attarchi , Mack H. Mabry , Wan-Jen Hong , Thomas Michael Jahn , Pierre Fenaux , Guillermo Garcia-Manero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

NCT02942290

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS7082)

DOI

10.1200/JCO.2018.36.15_suppl.TPS7082

Abstract #

TPS7082

Poster Bd #

137b

Abstract Disclosures

Similar Posters

First Author: Jacqueline Suen Garcia

First Author: Amer Methqal Zeidan

First Author: Ehab L. Atallah

First Author: Naval Guastad Daver